LION TCR和辽宁 - 大连旅顺区政府将开发癌细胞治疗研究和

StephenW

Lion TCR and Liaoning-Dalian Lvshun District Government to Develop Research and Manufacturing Facilities for Cancer Cell Therapies
[PR Newswire]
PR NewswireAugust 9, 2019
SINGAPORE, Aug. 9, 2019 /PRNewswire/ -- Lion TCR Pte. Ltd., a clinical-stage Biotech company focused on development of innovative engineered T cell immunotherapy against viral-related cancer and chronic Hepatitis B infection, announced on 29 July 2019 that it has signed an agreement with Dalian Lvshun District Government at the 10th Singapore-Liaoning Economic and Trade Council Meeting (SLETC) to develop cell manufacturing and research facilities for cancer treatment. The 5,000-sqm facility, built by Dalian Municipal Government, will support Lion TCR's development and commercialisation of cell therapy products in China in addition to Lion TCR's facility at the China-Singapore Guangzhou Knowledge City. Lion TCR shall utilize GMP (Good Manufacturing Practice) certified entities for the production of advanced cellular immunotherapy products for clinical trials and for future commercial products. The facility design and process will comply with both China CDE and internationally recognized GMP guidelines.

The 10th SLETC was chaired by Mr. Masagos Zulkifli, Singapore's Minister for the Environment and Water Resources, and Mr. Tang Yijun, Liaoning Governor, the Co-Chairmen of SLETC. At the council meeting, 11 Singapore companies including Lion TCR signed project agreements to provide greater connectivity, sustainability, technology and healthcare in Liaoning. Singapore is Liaoning's third largest foreign investor with a total investment of about S$19 billion (95 billion yuan). Minister Masagos told the Party Secretary and Mayor of Dalian City at their meeting: "Singapore looks forward to deepening cooperation with Dalian in environmental protection, new energy, interconnection, biomedical, petrochemical, marine fishery, food processing, sustainable development and other fields."

Mr Stephen Lim, CEO of Lion TCR commented that "Lion TCR looks forward to using this Dalian GMP cell therapy facilities as a manufacturing base for our China commercialisation needs. As a stand-alone building is required for cell therapy GMP application in China, this offer to build with option for Lion to purchase by the Dalian Government is a great help to Lion as it frees our immediate cashflow for continual research and on-going clinical trials."

About Lion TCR

Lion TCR is a Singapore-based clinical stage biotech company focused on development of engineered T cell immunotherapy against viral-related cancer and chronic hepatitis B infection with manufacturing and clinical trial operations in China and Singapore. It is the first company to develop HBV-specific TCR T cell therapy against liver cancer.

Lion TCR's engineered T cell technologies are exclusively licensed from Agency for Science, Technology and Research (A*STAR), Singapore (TCR-T cell therapy developed by Prof. Antonio Bertoletti's lab).

For more information about Lion TCR, please visit http://www.liontcr.com/

StephenW

狮子会TCR和辽宁 - 大连旅顺区政府将开发癌细胞治疗研究和制造设施
[美通社]
美通社2019年8月9日
新加坡，2019年8月9日/美通社/  -  Lion TCR Pte。有限公司是一家临床阶段的生物技术公司，专注于开发针对病毒相关癌症和慢性乙型肝炎感染的创新工程T细胞免疫疗法，于2019年7月29日宣布已与大连绿顺区政府在第10届新加坡签署协议 - 辽宁省经济贸易理事会会议（SLETC）致力于开发癌症治疗的细胞制造和研究设施。除了Lion TCR在中国 - 新加坡广州知识城的工厂外，由大连市政府建造的5,000平方米的设施将支持Lion TCR在中国开发和商业化细胞治疗产品。 Lion TCR应利用GMP（良好生产规范）认证实体生产用于临床试验和未来商业产品的高级细胞免疫治疗产品。设施设计和流程将符合中国CDE和国际公认的GMP指南。

第10届SLETC由新加坡环境与水资源部长Masagos Zulkifli先生和SLETC联合主席辽宁省省长唐义军先生主持。在理事会会议上，包括Lion TCR在内的11家新加坡公司签署了项目协议，以在辽宁提供更大的连通性，可持续性，技术和医疗保健。新加坡是辽宁第三大外国投资者，总投资额约为190亿新元（950亿元人民币）。马萨戈斯部长在大连市党委书记和市长的会见中说：“新加坡期待加强与大连在环境保护，新能源，互联，生物医药，石油化工，海洋渔业，食品加工，可持续发展等领域的合作。”

Lion TCR首席执行官Stephen Lim先生表示，“Lion TCR期待将大连GMP细胞疗法设施作为我们中国商业化需求的制造基地。作为一个独立的建筑，GMP应用于中国需要一个独立的建筑，大连政府为Lion购买狮子会的选择建议对Lion来说是一个很大的帮助，因为它可以让我们立即获得现金流，用于持续研究和正在进行的临床试验。“

关于Lion TCR

Lion TCR是一家总部位于新加坡的临床阶段生物技术公司，专注于开发针对病毒相关癌症和慢性乙型肝炎感染的工程化T细胞免疫疗法，并在中国和新加坡进行制造和临床试验。它是第一家开发针对肝癌的HBV特异性TCR T细胞疗法的公司。

Lion TCR的工程T细胞技术由新加坡科学，技术和研究机构（A * STAR）独家授权（由Antonio Bertoletti教授的实验室开发的TCR-T细胞疗法）。

有关Lion TCR的更多信息，请访问http://www.liontcr.com/

齐欢畅